Answers are grounded in this paper and cite their sources.
Last week, the Department of Health and Human Services (HHS) announced two new investments to promote the development of psychedelics to treat mental illness. First, the National Institute of Mental Health (NIMH) published a $20 million notice of funding opportunity to support the development of a research network to study rapid‐acting psychotropic interventional drugs such as ketamine, esketamine, psilocybin and other emerging treatments for serious mental illnesses. Second, investments up to $4.9 million through the Advanced Research Projects Agency for Health (ARPA‐H) were announced to advance the development of ibogaine as a potential treatment for post‐traumatic stress disorder (PTSD) and other serious mental illnesses.
No takes yet. Share an insight, caveat, or question.
Alison Knopf (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: